BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an ...

BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the ...

On August 2, 2018, BioTime Inc. (NYSE: BTX; $2.31; market capitalization: $293 million) announced results for 2Q18. BioTime primary clinical programs Renevia and OpRegen progressed on research and ...

06 September 2006 BioLink Solutions announces the upcoming advertising campaign targeted at potential customers for its biometric time management system - BioTime. The campaign starts in September 1, ...

BioTime, Inc., a pioneer in regenerative medicine and a clinical-stage biotechnology company, has received 27 new patents protecting stem cell-based product development during the first half of 2015.

Company says it estimates initial annual revenue of approximately $1 million ORLANDO, Fla. -- Sequiam Corporation, through its wholly-owned subsidiary Sequiam Biometrics, Inc.

BioTime (BTX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.09 per share a year ago. These figures ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) announced today that its Senior Vice President and Chief Operating Officer, Robert W. Peabody, will reassume the additional role of ...

BioTime, Inc. (LCTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates - ...